The Critical Role of Particle Characterisation in Pharmaceutical Development
In an industry where the average drug takes over a decade to move from discovery to market, any technology that can accelerate development timelines while maintaining the highest quality standards represents a significant competitive advantage. Particle characterisation has emerged as one of the most impactful analytical disciplines in modern pharmaceutical development, providing essential data that influences every stage of the drug product lifecycle β from early-stage formulation screening through to final product release testing.
The physical properties of drug particles β their size, shape, surface area, charge, and crystalline form β have a profound impact on the performance of the final dosage form. A seemingly minor change in particle size distribution can dramatically affect dissolution rate, bioavailability, content uniformity, and even patient compliance. This is why regulatory agencies worldwide have increasingly emphasised the importance of comprehensive particle characterisation as part of a robust quality-by-design (QbD) framework.
Key Analytical Techniques for Pharmaceutical Particles
Modern pharmaceutical development relies on a suite of complementary particle characterisation techniques, each providing unique and essential information:
- Laser diffraction: The gold standard for measuring particle size distributions across the range from hundreds of nanometres to several millimetres. The Malvern Panalytical Mastersizer delivers highly reproducible, method-robust measurements that satisfy pharmacopoeial requirements.
- Dynamic light scattering (DLS): Essential for characterising sub-micron and nanoparticle formulations including liposomes, protein aggregates, and polymeric nanocarriers. The Zetasizer platform provides simultaneous size, zeta potential, and molecular weight data.
- Nanoparticle tracking analysis (NTA): The NanoSight system counts and sizes individual nanoparticles in real time, providing high-resolution size distributions and concentration data critical for exosome research and nanomedicine development.
- BET surface area analysis: Surface area measurements reveal the reactivity and dissolution potential of drug substances, particularly important for poorly water-soluble compounds.
- X-ray powder diffraction: XRD confirms the polymorphic form and crystallinity of active pharmaceutical ingredients, ensuring batch-to-batch consistency and thermodynamic stability.
From Formulation to Manufacturing
In early-stage formulation development, particle characterisation guides the selection of milling strategies, excipient compatibility studies, and process parameters. Scientists use laser diffraction to monitor wet milling and high-pressure homogenisation processes in real time, ensuring that target particle size specifications are achieved before moving to scale-up.
During scale-up and technology transfer, inline and at-line particle sizing provides the process understanding needed to maintain product quality across different manufacturing sites and equipment configurations. The ability to measure particle size in real time β whether in a granulation vessel, spray dryer, or coating pan β enables process analytical technology (PAT) strategies that reduce batch failures and accelerate process validation.
Regulatory Expectations and Quality by Design
The ICH Q8, Q9, and Q10 guidelines have established a regulatory framework that encourages pharmaceutical companies to develop deep process understanding through systematic analytical characterisation. Particle size is explicitly recognised as a critical quality attribute (CQA) for most solid oral dosage forms, inhaled products, and parenteral formulations.
Regulatory submissions that include comprehensive particle characterisation data demonstrate a thorough understanding of the product and process, often resulting in faster review times and fewer questions from assessors. The investment in robust particle analysis during development pays dividends throughout the product lifecycle, enabling confident lot release decisions and efficient investigation of out-of-specification results.
Enabling the Future of Pharmaceutical Innovation
As the pharmaceutical industry embraces increasingly complex modalities β from mRNA lipid nanoparticles to cell and gene therapies β the demand for sophisticated particle characterisation will only intensify. Advanced techniques capable of measuring multi-parameter profiles on individual particles, combined with data analytics platforms that can extract meaningful patterns from complex datasets, will be essential for developing the next generation of life-changing medicines.
Malvern Panalytical's comprehensive portfolio of particle characterisation instruments, combined with deep application expertise and global support capabilities, positions pharmaceutical scientists to meet these challenges with confidence β accelerating the journey from molecule to medicine while ensuring the highest standards of quality and safety.